Global Myasthenia Gravis Treatment Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, IVIg, and Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Myasthenia Gravis Treatment Market Insights Forecasts to 2035

• The Global Myasthenia Gravis Treatment Market Size Was Estimated at USD 1.51 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.72% from 2025 to 2035
• The Worldwide Myasthenia Gravis Treatment Market Size is Expected to Reach USD 3.42 Billion by 2035
• Asia Pacific is Expected to Grow the Fastest during the forecast period.

The Global Myasthenia Gravis Treatment Market Size was Worth around USD 1.51 Billion in 2024 and is predicted to Grow to around USD 3.42 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 7.72% from 2025 to 2035. The Market Size  for myasthenia gravis treatment is made possible by the pharmaceutical industry's growth and advancements in producing medications for the condition, which are driven by a large number of health-conscious consumers.   

Market Overview

The Global Industry Devoted to creating and disseminating treatment solutions for myasthenia gravis (MG), a chronic autoimmune neuromuscular condition that results in muscle weakening, is known as the myasthenia gravis treatment market. Numerous therapeutic techniques are covered by this market, including immunosuppressants, corticosteroids, cholinesterase inhibitors, monoclonal antibodies, plasma exchange, and surgical procedures.  

The Market Size is primarily driven by the condition's rising prevalence and the strong efforts of major companies in the study and creation of medications and treatments. For Instance, in October 2023, the FDA approved UCB S.A.'s ZILBRYSQ (zilucoplan) to treat individuals with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).

A major factor propelling the growth of the myasthenia gravis treatment market is the rising incidence of the condition globally. The prevalence of myasthenia gravis is rising, which is predicted to fuel demand for efficient therapies. The rising incidence of myasthenia gravis, awareness of early diagnosis, and uptake of innovative treatment options are the primary factors driving the market's expansion. 

Report Coverage

This research report categorizes the myasthenia gravis treatment market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the myasthenia gravis treatment market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the myasthenia gravis treatment market. 

Driving Factors

Government programs to raise awareness of myasthenia gravis and upgrade healthcare facilities are also driving market expansion. The availability of better healthcare infrastructure, the rise in unmet healthcare needs, the prevalence of autoimmune diseases, and the surge in demand for new medications to treat myasthenia gravis are all anticipated to boost the growth of the myasthenia gravis treatment market in emerging markets. The expansion of the myasthenia gravis treatment industry has been aided by health applications that use animations to teach users about the disease and the best way to take medications.   

Restraining Factors

The adverse effects of medications like immunosuppressants and corticosteroids, such as weight gain, mood swings, gastrointestinal issues, and an increased risk of infection, might affect patient compliance and restrict myasthenia gravis treatment market.   

Market Segmentation

The myasthenia gravis treatment market share is classified into drug class and distribution channel. 

• The IVIg segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the drug class, the myasthenia gravis treatment market is divided into cholinesterase inhibitors, corticosteroids, immunosuppressants, IVIg, and monoclonal antibodies. Among these, the IVIg segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The reduced preference resulting from the adverse effects of traditional therapy is the reason for the IVIg segment. Furthermore, IVIG treatment offers patients are not responding to traditional medicines a long-term, safe, and effective form of therapy.

• The hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the myasthenia gravis treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The increase in hospitalizations and doctor visits is the reason for the hospital pharmacies. Approximately 15–25% of patients experience a myasthenia crisis during treatment at some point, necessitating hospitalization due to medication side effects.  

Regional Segment Analysis of the Myasthenia Gravis Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the myasthenia gravis treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the myasthenia gravis treatment market over the predicted timeframe. North America is due to its high incidence of the condition, increased autoimmune disease detection rates, sophisticated healthcare infrastructure, and presence of significant manufacturers offering innovative medicines. In addition, both emerging and developed nations are seeing improvements in the identification and treatment of the ailment due to the region's well-developed healthcare infrastructure and advantageous reimbursement policies. These elements are expected to propel the market.   

Asia Pacific is expected to grow at a rapid CAGR in the myasthenia gravis treatment market during the forecast period. The Asia Pacific due to the region's strong domestic business presence, expanding industry infrastructure, and rising autoimmune disease spending. Electromyography (EMG), nerve conduction investigations, blood tests to identify antibodies, and physical examinations are the most frequently used diagnostic procedures for myasthenia gravis. Additionally, the growth of contract manufacturing companies in the area offers newcomers in this market a lot of opportunities.

Europe is predicted to hold a significant share of the myasthenia gravis treatment market throughout the estimated period. In order to identify and treat uncommon illnesses like myasthenia gravis, Europe has established a number of healthcare organizations and increased financing. A 2019 article in a European national journal indicates that the European Joint Programme on Rare Diseases was created to enhance detection and create efficient therapies for rare diseases in related EU member states.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the myasthenia gravis treatment market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie Inc.
• Grifols SA
• Shire plc
• Pfizer, Inc.
• Novartis
• F.Hoffmann-La Roche AG
• GlaxoSmithKline Plc.
• Alexion Pharmaceutical Inc.
• Bausch Health Companies Inc.
• Avadel Pharmaceuticals, Plc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In September 2023, Recipharm AB partnered with AHEAD THERAPEUTICS S.L. to develop a new therapy for myasthenia gravis. This partnership aids to scale up the manufacturing capacity of myasthenia gravis products.

• In August 2023, The Japanese government has approved Astrazeneca's Soliris (eculizumab) to treat generalized myasthenia gravis (gMG) in children with anti-acetylcholine receptor (AChR) antibodies.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the myasthenia gravis treatment market based on the below-mentioned segments: 

Global Myasthenia Gravis Treatment Market, By Drug Class

• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• IVIg
• Monoclonal Antibodies

Global Myasthenia Gravis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Myasthenia Gravis Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa